|

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

RECRUITINGPhase 2Sponsored by Gateway Institute for Brain Research
Actively Recruiting
PhasePhase 2
SponsorGateway Institute for Brain Research
Started2022-02-07
Est. completion2026-12-01
Eligibility
Age30 Years – 85 Years
Healthy vol.Accepted
Locations2 sites

Summary

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Eligibility

Age: 30 Years – 85 YearsHealthy volunteers accepted
Key Inclusion Criteria:

* Documented clinical diagnosis of idiopathic PD
* Modified HY stage \< 5
* Able to administer study drug or have a caregiver throughout the duration of the study to help administer drug
* Willing to continue diet, exercise and medications reported at baseline consistently throughout participation in the trial. Essential changes are permitted
* If taking PD medications or any nutraceuticals, must be on a stable dose for at least 30 days prior to Screening Visit. Essential changes will be permitted.
* If subject is taking chronic antidepressant or an anxiolytic, must be on a stable dose for at least 90 days prior to Screening. Essential changes will be permitted.

Key Exclusion Criteria:

* Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus
* Glycated hemoglobin (HbA1c) level ≥ 6.5%
* History of hypoglycemia and/or documented plasma glucose levels of ≤ 50 mg/dL with or without symptoms of hypoglycemia
* Mini-Mental State Exam (MMSE) score of ≤ 24 at Screening
* Positive COVID-19 test at Screening and/or within 30 days of Screening
* Change in or escalation of dose of a chronic therapeutic agent that has the potential to impair cognitive functioning
* Chronic inflammation of nasal cavity that may prevent absorption of study treatments
* Insufficiently controlled respiratory disease (i.e., asthma, COPD).
* History of any significant neurologic or psychiatric disease other than PD
* Current diagnosis of epilepsy and had a history of seizures as an adult within 1 year of Screening, or unexplained recent loss of consciousness, or history of significant head trauma with loss of consciousness
* History of non-lacunar ischemic and/or hemorrhagic stroke
* Unstable or uncontrolled cardiac disease that could expose the subject to additional safety risks
* Use of the following medications: Insulin or any other anti-hyperglycemic agent(s) except if used during isolated gestational diabetes, Supplementation with GSH or any medication shown to increase glutathione, and Beta Blockers

Conditions2

Parkinson DiseaseParkinson's Disease

Locations2 sites

Institute for Neuroimmune Medicine
Davie, Florida, 33314
Rafael Iglesias954-262-2876ri73@nova.edu
Las Mercedes Medical Research
Hialeah, Florida, 33012
Ariadna Zarzuela, RN, BSN786-577-5977ariadna.zarzuela@lmmresearch.com

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.